萊莫維韋

{{Drugbox
| IUPAC_name = {(4S)-8-Fluoro-2-[4-(3-methoxyphenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetic acid
| image = Letermovir skeletal.svg
| alt =
| caption =

| tradename =
| Drugs.com =
| MedlinePlus =
| pregnancy_AU =
| pregnancy_US =
| pregnancy_category=
| legal_AU =
| legal_CA =
| legal_UK =
| legal_US =
| legal_status = Investigational
| routes_of_administration = Oral

| bioavailability =
| protein_bound =
| metabolism =
| elimination_half-life =
| excretion =

| CAS_number =
| ATCvet =
| ATC_prefix = None
| ATC_suffix =
| PubChem = 45138674
| UNII_Ref =
| UNII = 1H09Y5WO1F
| DrugBank =
| ChemSpiderID = 26352849
| ChEMBL = 1241951
| synonyms = AIC246
| KEGG_Ref =
| KEGG = D10801

| C=29 | H=28 | F=4 | N=4 | O=4
| molecular_weight = 572.55 g/mol
| smiles = COC1=C(C=C(C=C1)C(F)(F)F)N2C@HF)N=C2N4CCN(CC4)C5=CC(=CC=C5)OC)CC(=O)O
| StdInChI=1S/C29H28F4N4O4/c1-40-20-6-3-5-19(16-20)35-11-13-36(14-12-35)28-34-27-21(7-4-8-22(27)30)23(17-26(38)39)37(28)24-15-18(29(31,32)33)9-10-25(24)41-2/h3-10,15-16,23H,11-14,17H2,1-2H3,(H,38,39)/t23-/m0/s1
| StdInChIKey = FWYSMLBETOMXAG-QHCPKHFHSA-N
}}

萊莫維韋（Letermovir）是一種用於治療巨細胞病毒感染的藥物。本藥物已經於骨髓移植併發巨細胞感染的患者身上測試，且可能也對HIV感染或器官移植後等免疫功能不良的患者有相同療效。

本品已被美國食品藥品監督管理局給予快速審查資格，也獲得歐洲藥品管理局的罕用藥資格。

參考文獻